Use of class I histone deacetylase inhibitor romidepsin in combination regimens

Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma

(2015) A. McBride et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma

(2015) Enrica Marchi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma

(2015) S. Jain et al.   CLINICAL CANCER RESEARCH

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas

(2015) E. A. Chong et al.   CLINICAL CANCER RESEARCH

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin

(2015) Philip T. Sager et al.   Cancer Medicine

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study

(2015) Jehan Dupuis et al.   Lancet Haematology

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

(2014) Bertrand Coiffier et al.   Journal of Hematology & Oncology

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)

(2014) Sarah I. Jawed et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

(2014) Nathan H Fowler et al.   LANCET ONCOLOGY

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

(2013) Vivien Mak et al.   JOURNAL OF CLINICAL ONCOLOGY

Methods for Identifying Higher-Order Chromatin Structure

(2012) Samin A. Sajan et al.   Annual Review of Genomics and Human Genetics

Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions

(2012) O.E. Akilov et al.   BRITISH JOURNAL OF DERMATOLOGY

Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors

(2012) Suzanne F. Jones et al.   CANCER INVESTIGATION

Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer

(2012) Andrew J. Wilson et al.   GYNECOLOGIC ONCOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin

(2012) Youn H. Kim et al.   LEUKEMIA & LYMPHOMA

HDAC inhibitor-based therapies: Can we interpret the code?

(2012) Maria New et al.   Molecular Oncology

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

(2011) S. J. Harrison et al.   BLOOD

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

(2011) M. Kalac et al.   BLOOD

Peripheral T-cell lymphoma

(2011) F. M. Foss et al.   BLOOD

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

(2010) J. Kikuchi et al.   BLOOD

A work in progress: The clinical development of histone deacetylase inhibitor

(2010) Silvia Marsoni et al.   Epigenetics

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

(2010) Nita Sally Agar et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

(2010) R Shimizu et al.   LEUKEMIA

How I treat mycosis fungoides and Sezary syndrome

(2009) H. M. Prince et al.   BLOOD

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

(2009) Thomas E. Witzig et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines

(2009) Wei Zhang et al.   Journal of Thoracic Oncology

Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib

(2008) F.-T. Liu et al.   BLOOD

Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells

(2008) Y. Dai et al.   CLINICAL CANCER RESEARCH

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression

(2007) Vinodhkumar Radhakrishnan et al.   BIOMEDICINE & PHARMACOTHERAPY